Related Experiment Video
Updated: Aug 21, 2026

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
[Treatment of severe preeclampsia and HELLP syndrome]
1Klinik für Gynäkologie und Geburtshilfe des Universitätsklinikums Aachen. wrath@ukaachen.de.
Insights
Severe preeclampsia and HELLP syndrome require prompt management for maternal and fetal health. Early diagnosis, intensive monitoring, and appropriate treatment, including magnesium sulfate and timely delivery, significantly reduce mortality rates.
Area of Science:
- Obstetrics and Gynecology
- Maternal-Fetal Medicine
- Critical Care Medicine
Context:
- Severe preeclampsia and HELLP syndrome are significant causes of maternal and perinatal mortality.
- Accurate definitions and timely interventions are crucial for effective patient management.
Purpose:
- To outline current therapeutic strategies for severe preeclampsia and HELLP syndrome.
- To emphasize the importance of specialized perinatal center care and intensive monitoring.
Summary:
- Management includes anticonvulsive prophylaxis (magnesium sulfate), blood pressure control (urapidil/nifedipine), volume expansion, and coagulation disorder treatment (fresh frozen plasma).
- Delivery is indicated at >= 34 weeks' gestation; cesarean section is preferred for unripe cervix with HELLP syndrome.
- Expectant management with intensive monitoring is possible for patients < 34 weeks' gestation, with careful consideration of maternal/fetal indications for delivery.
Impact:
- Increased awareness and multidisciplinary collaboration have reduced maternal mortality to <1% and perinatal mortality to 9.4-16.2% for HELLP syndrome.
- Systemic corticosteroids show promise in prolonging pregnancy, improving outcomes in West European countries.
Abstract:
Severe preeclampsia and HELLP syndrome are still one of the leading causes of maternal and perinatal morbidity and mortality. The current definitions of the diseases should be considered before treatment. The timely allocation to a perinatal center and an intensive monitoring of mother and child after admission are mandatory for successful management of these patients. The aim of therapy is immediate stabilization of the mother's condition by means of anticonvulsive prophylaxis with intravenous magnesium sulphate, well-controlled reduction of blood pressure by the administration of urapidil or nifedipine, controlled volume expansion and an adequate treatment of coagulation disorders by giving fresh frozen plasma (not heparin). Immediate delivery is the method of choice in cases of severe preeclampsia/HELLP syndrome > or = 34 weeks' gestations; we prefer cesarean section in patients with an unripe cervix and the full-blown picture of HELLP syndrome. In patients < 34 weeks' gestation expectant management is generally possible under intensive monitoring of the mother and the fetus. Maternal and fetal indications for immediate termination of pregnancy should be considered carefully. The systemic application of corticosteroids is a promising approach to prolong pregnancy. During the past decade the increasing awareness of obstetricians and other disciplines have led to a significant reduction of maternal mortality (< 1 %) and perinatal mortality (9.4-16.2 %) in cases of HELLP syndrome, in particular in the West European countries.
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Nephrotic Syndrome III : Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Heart Failure VI: Adjunct Therapies